Frille Armin, Boeschen Myriam, Wirtz Hubert, Stiller Mathias, Bläker Hendrik, von Laffert Maximilian
Department of Respiratory Medicine, Leipzig University, Leipzig, Germany.
Institute of Pathology, Leipzig University, Leipzig, Germany.
Front Oncol. 2024 Apr 22;14:1357583. doi: 10.3389/fonc.2024.1357583. eCollection 2024.
Recently, we could show that the co-mutations of + , + and + + lead to a significantly shorter median overall survival (mOS) across treatments by analyzing multiple datasets. , a tumor suppressor gene, plays a crucial role in regulating cell cycle progression. Its mutations occur in approximately 40-50% of non-small lung cancer (NSCLC). Co-occurrence of all four mentioned mutations has been a matter of debate for years. The aim of this study was to assess the distribution of these four mutations and the influence of the different co-mutational patterns on survival.
We present a comparative bioinformatic analysis and refer to data of 4,109 patients with lung adenocarcinoma (LUAD).
Most of the mutations within the LUAD belong to -only (29.0%), quadruple-negative (25.9%) and -only (13.4%). Whereas seem to have protective effects in the context of further and + alterations (improved mOS), their role seems contrary if acquired in an already existing combination of mutations as + + + and + . co-mutationshad a negative influence on -only mutated LUAD (mOS reduced significantly by more than 30%).
These data underline the need for complex mutational testing to estimate prognosis more accurately in patients with advanced LUAD.
最近，通过分析多个数据集，我们发现 + 、 + 以及 + + 共同突变会导致各种治疗方式下的中位总生存期（mOS）显著缩短。 是一种肿瘤抑制基因，在调节细胞周期进程中起关键作用。其突变约发生在40%-50%的非小细胞肺癌（NSCLC）中。这四种突变共同出现的情况多年来一直存在争议。本研究的目的是评估这四种突变的分布情况以及不同共同突变模式对生存的影响。
我们进行了一项比较生物信息学分析，并参考了4109例肺腺癌（LUAD）患者的数据。
LUAD中的大多数突变仅属于 （29.0%）、四重阴性（25.9%）和 （13.4%）。在存在进一步的 和 + 改变的情况下， 似乎具有保护作用（mOS改善），但如果在已有的 + + + 和 + 突变组合中出现，其作用似乎相反。 共同突变对仅发生 突变的LUAD有负面影响（mOS显著降低超过30%）。
这些数据强调了进行复杂突变检测以更准确估计晚期LUAD患者预后的必要性。
